Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alk Abello A/S presents Phase III data on house dust mite SLIT-tablet


Monday, 9 Jun 2014 07:50am EDT 

Alk Abello A/S:Presented key trial results on new sublingual allergy immunotherapy tablet (SLIT-tablet) for house dust mite (HDM) respiratory allergic diseases.ALK HDM SLIT-tablet works by addressing underlying causes of HDM respiratory allergic diseases.Says it is first allergy immunotherapy product with comprehensive clinical development programme aimed at treating both upper and lower airway manifestations of HDM-induced allergic respiratory diseases (namely allergic rhinitis and allergic asthma, respectively).MITRA trial met its primary clinical endpoint.Patients who received the dose of 12 SQ-HDM experienced significant improvement in their asthma control as evident by 34 pct reduction in risk of suffering moderate-to-severe asthma exacerbation during withdrawal of inhaled corticosteroids.Phase 2 and 3 data presented demonstrated an onset of action with the 12 SQ-HDM dose as early as 8 to14 weeks post initiation of treatment.Both the MITRA and MERIT trials also demonstrated that the treatment was well tolerated and had a favourable safety profile. 

Company Quote

662.0
-6.0 -0.90%
19 Dec 2014